Can an AI chatbot teach better sleep habits to young adults at risk?

NCT ID NCT05956886

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study explores whether an AI-powered chatbot can deliver personalized sleep coaching to Black/African American adults aged 18-25 who have poor sleep and at least one cardiometabolic risk factor. The chatbot uses principles of cognitive-behavioral therapy for insomnia (CBT-I) to set sleep goals and provide weekly guidance. Researchers will measure how acceptable and feasible the chatbot is, and whether it improves sleep quality, duration, and regularity. The goal is to see if this approach could offer a scalable way to address sleep problems in a group that often lacks tailored sleep interventions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
An artificial intelligence chatbot delivering cognitive-behavioral therapy for insomnia (CBT-I) principles, including sleep restriction and stimulus control, with personalized goal-setting and weekly behavioral prescriptions.
What this could lead to
If successful, this could lead to a scalable, culturally tailored digital tool to improve sleep and reduce cardiometabolic risk in young Black adults.
What could go wrong
This is a small feasibility study, so results may not generalize. The chatbot's effectiveness and long-term impact remain uncertain, and there are no guarantees it will outperform standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSOMNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Delaware

    Newark, Delaware, 19716, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.